Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,683.00+1.28%ETH$2,286.51+1.78%GOLD$3,940.20-0.74%OIL$96.76+0.31%
Smart Investors Daily
SID Premium
Enanta Pharmaceuticals, Inc. logo

NASDAQ · ENTA

Enanta Pharmaceuticals, Inc.

Healthcare · Biotechnology

$10.43

Down-$0.06 (-0.58%)

Updated Nov 3, 2026, 9:19 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
301.87M
P/E ratio
-3.69
Dividend yield
0.00%
52-week range
$10.14 – $17.15
Volume
350.76K
Avg. volume
750.44K

Price performance · ENTA

ENTA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ENTA closed at $10.43 after 21 trading sessions, down 17.22% for the selected period.

Last close
$10.43
Period change
-17.22%
Period low
$10.43
Period high
$12.60
Daily close
View OHLC price history
ENTA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$10.74$10.91$10.14$10.43350.76K
Oct 30, 2026$11.08$11.10$10.69$10.71202.34K
Oct 29, 2026$11.65$11.74$10.76$11.15218.49K
Oct 28, 2026$11.20$11.77$10.7035$11.55282K
Oct 27, 2026$11.98$12.395$11.86$12.18319.43K
Oct 26, 2026$11.73$12.06$11.65$12.00440.62K
Oct 23, 2026$11.57$11.68$10.97$11.64228.23K
Oct 22, 2026$11.31$11.625$11.085$11.62200.63K
Oct 21, 2026$11.64$11.85$11.24$11.31166.83K
Oct 20, 2026$11.43$11.85$11.41$11.67164.92K
Oct 19, 2026$11.14$11.76$11.00$11.41293.41K
Oct 16, 2026$11.65$11.65$10.945$11.10215.41K
Oct 15, 2026$11.34$11.75$11.22$11.47178.43K
Oct 14, 2026$11.44$11.565$11.145$11.18227.61K
Oct 13, 2026$12.37$12.37$11.39$11.52173.99K
Oct 12, 2026$12.48$12.635$12.15$12.30122.89K
Oct 9, 2026$12.07$12.61$12.07$12.50182.07K
Oct 8, 2026$12.26$12.35$11.70$12.10282.9K
Oct 7, 2026$12.09$12.57$12.05$12.37191.67K
Oct 6, 2026$12.66$12.66$11.97$12.17271.7K
Oct 5, 2026$12.95$13.025$12.47$12.60218.88K

Latest ENTA news

The latest Smart Investors Daily articles mentioning ENTA.

Stock researchCompany · Overview

ENTA research

Overview

Company profile and research snapshot.

Company profile

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$20.00
Implied upside
—
Analysts
—
ENTA recent ratings
DateFirmRatingTarget
Sep 23, 2026HC Wainwright & Co.Buy—
Jun 23, 2026HC Wainwright & Co.Buy—
Feb 10, 2026HC Wainwright & Co.Buy—
Jan 9, 2026HC Wainwright & Co.Buy—
Nov 14, 2025JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass., October 26, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027.

Yahoo · Oct 13, 2026

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

WATERTOWN, Mass., October 13, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center i

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By